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Abstract
Background: The NMDA receptor antagonist ketamine was found to act as a fast-acting antidepressant. The effects
of single treatment were reported to persist for days to weeks, even in otherwise treatment-refractory cases.
Identification of the mechanisms underlying ketamine’s antidepressant action may permit development of novel
drugs, with similar clinical properties but lacking psychotomimetic, sedative and other side effects.
Methods: We applied whole-genome microarray profiling to analyze detailed time-course (1, 2, 4 and 8 h) of
transcriptome alterations in the striatum and hippocampus following acute administration of ketamine, memantine
and phencyclidine in C57BL/6 J mice. The transcriptional effects of ketamine were further analyzed using
next-generation sequencing and quantitative PCR. Gene expression alterations induced by the NMDA antagonists
were compared to the molecular profiles of psychotropic drugs: antidepressants, antipsychotics, anxiolytics,
psychostimulants and opioids.
Results: We identified 52 transcripts (e.g. Dusp1, Per1 and Fkbp5) with altered expression (FDR < 1 %) in response to
treatment with NMDA receptor antagonists. Functional links that connect expression of the regulated genes to the
MAPK, IL-6 and insulin signaling pathways were indicated. Moreover, ketamine-regulated expression of specific
gene isoforms was detected (e.g. Tsc22d3, Sgk1 and Hif3a). The comparison with other psychotropic drugs revealed
that the molecular effects of ketamine are most similar to memantine and phencyclidine. Clustering based on
expression profiles placed the NMDA antagonists among fluoxetine, tianeptine, as well as opioids and ethanol.
Conclusions: The identified patterns of gene expression alteration in the brain provided novel molecular
classification of ketamine. The transcriptional profile of ketamine reflects its multi-target pharmacological nature. The
results reveal similarities between the effects of ketamine and monoaminergic antidepressants that may explain the
mechanisms of its rapid antidepressant action.
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Background
Ketamine is a dissociative anaesthetic that causes profound
analgesia and amnesia. Recently, there has been growing
interest in the reported antidepressant effects of ketamine.
Due to the almost immediate onset of antidepressant
effects ketamine could potentially be particularly useful in
acute treatment of depression [1]. This rapid-onset anti-
depressant action provides a novel potential approach for
treatment-resistant major depressive disorder (MDD).
However, clinical application of ketamine is limited by its
psychotomimetic effects and rewarding properties, which
are responsible for its recreational use and abuse [2].
Ketamine is a noncompetitive antagonist of the NMDA
glutamate receptor, with affinities for other receptors and
transporters, including dopamine D2 and opioid receptors
as well as monoamine transporters [3–6]. The complex
pharmacological profile of ketamine makes it difficult to
postulate a specific mechanism of its rapid antidepressant
effect. The comparison with other NMDA receptor
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antagonists does not provide clear indication of the pos-
sible mechanism of action [7, 8]. Phencyclidine (PCP) in-
duces cognitive disruption and psychotic-spectrum
reactions but, unlike ketamine, was not observed to have
antidepressant effects in humans. Memantine, a drug with
moderate-affinity for NMDA receptors and without the
adverse effects, also does not show evidence of rapid anti-
depressant effects in depressed patients [9]. Thus, the
antidepressant effects are specific to ketamine and result
from unique combination of its receptor targets and trig-
gered neuronal mechanisms. Elucidating the mechanism
of ketamine action would provide an important insight
into the molecular correlates underlying the efficacy of
rapid antidepressants and also suggest a useful approach
for screening of novel compounds.
Ketamine facilitates neuronal plasticity in brain areas
implicated in MDD, including the hippocampus, the pre-
frontal cortex and the striatum. It has been shown that
ketamine enhances mammalian target of rapamycin
(mTOR) and increases expression of the brain-derived
neurotrophic factor (BDNF), resulting in modification to
the number and function of synaptic connections [10, 11].
These alterations are related to activation of downstream
intracellular signaling pathways and transcription of genes
[12]. Therefore, the analysis of transcriptional programs
associated with rapid action of ketamine may provide
novel insight into the molecular mechanisms underlying
specific behavioral effects of this drug.
In this study, we used gene expression profiling to
compare ketamine with PCP and memantine based on
their transcriptional effects in the striatum and hippo-
campus. Furthermore, we have analyzed the molecular
profile of the selected NMDA antagonists in comparison
to over a dozen of antidepressants, antipsychotics, psy-
chostimulants, anxiolytics and opioids [13]. Our results
identify differences as well as similarities between gene
expression alterations induced by ketamine and other
psychotropic drugs that may explain the unique psycho-
active properties of ketamine and its rapid antidepres-
sant effects. This study provides also a molecular
classification of ketamine among psychotropic drugs
based on the whole-transcriptome expression profile.
Results
Time-course of gene expression alterations induced by
the selected NMDA receptor ligands
First, we have analyzed alterations in the gene expression
profile in the striatum and hippocampus following single
administration of ketamine, memantine or PCP. The
analysis of alterations in mRNA abundance levels was
performed using whole-genome Illumina WG-6 micro-
arrays at four time points (1, 2, 4 and 8 h following drug
injection). Array data were subjected to three-way ana-
lysis of variance (ANOVA) with drug, time and tissue as
factors (Additional file 1). We found 52 drug-responsive
transcripts (Fig. 1) at the threshold of 1 % FDR (nominal
p = 1.15 × 10−5) with fold change greater than 0.5 (at least
at one time point for one of the drugs). We found moder-
ately higher transcriptional effects of memantine treat-
ment comparing to ketamine and PCP (Additional file 2).
At the same statistical threshold of 1 % FDR, 258 tran-
scripts with differential expression for the time factor
(nominal p = 5.6 × 10−5) and 21.316 transcripts for the tis-
sue factor (nominal p = 6.4 × 10−3) were identified. The re-
sults for the time factor (4 time points) indicated genes
altered during the diurnal cycle such as e.g. Dbp, Ciart
and Per2. The observed distinction between basal gene
expression profiles in the striatum and the hippocampus
was in line with expectations. The largest number of
differences in gene expression was observed in case of
neuron-type specific markers e.g. Pdyn, Rgs9 and Tac1.
Hierarchical clustering and functional enrichment analysis
of drug-responsive genes
Hierarchical clustering revealed three clusters of drug-
regulated genes (arbitrarily labeled as C1, C2 and C3).
Gene clusters C1 and C2 consisted of transcripts with
increased mRNA abundance levels in response to drug
treatment (Fig. 1). Cluster C1 was induced 1 h after in-
jection of ketamine and PCP and 1 to 2 h after injection
of memantine. Cluster C2 was induced 2 to 4 h by the
three selected drugs to different degrees. Example genes
from each cluster include: Dusp1, Per1, Sgk1 (C1) and
Fkbp5, Slc2a1, Map3k6 (C2). Cluster C3 includes two
down-regulated genes Fgf11 and Hes5. In addition, func-
tional enrichment analysis was used to investigate cell
signaling pathways related to drug-induced gene expres-
sion patterns (as shown in Fig. 1, right side). Enrichr, a
gene signature search tool based on the WikiPathways
database, indicated overrepresentation of genes involved
in MAPK (p = 0.0005) and IL-6 (p = 0.002) signaling
pathways among C1 gene cluster. Furthermore, the en-
richment analysis found genes from C2 cluster to be in-
volved in insulin signaling (p = 0.004; Additional file 3).
The comparison of transcriptional effects in the striatum
and hippocampus
The overall differences in drug-induced gene expression
between striatum and hippocampus were compared
using two-way ANOVA for drug and time factors
performed separately in each tissue. We found 62 tran-
scripts regulated by drug treatment in the hippocampus
and 62 transcripts altered in the striatum (at p < 0.0005,
absolute fold > 0.3 at least at one time point). The exam-
ples of regulated genes are Dbp and Mat2a in the hippo-
campus, and Fgf11 and Scrt2 in the striatum. We found 19
of the genes to be regulated in both the analyzed tissues,
including Dusp1, Sgk1 and Sult1a1 (Additional file 4). The
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pattern of gene expression alterations over time was
similar for all the selected NMDA antagonists (Additional
file 5). In the hippocampus the most substantial increase
in mRNA abundance levels was observed 1 h following
the administration of ketamine, 2 h after memantine and
2 to 4 h after PCP. The strongest response to each drug in
the striatum was observed at 2 to 4 h after injection. Time
course of expression alterations of down-regulated genes
corresponded to the pattern observed for up-regulated
genes.
The comparison of transcriptional effects of the selected
NMDA antagonists
To compare differences and similarities in gene expres-
sion after administration of ketamine, memantine and
PCP we performed two-way ANOVA with drug and
time factors for each drug and tissue separately (Fig. 2).
The similarities in molecular effects of the selected
NMDA antagonists are presented on Venn diagrams.
The overlap between each pair of drugs was tested using
Fisher’s exact test and proved to be significant in each
Fig. 1 Gene expression alterations induced by NMDA receptor antagonists in mouse hippocampus and striatum. Microarray results are shown as
a heat map and include genes with a genome-wide significance from three-way ANOVA for the drug factor (FDR < 0.01 and log2 fold change >
0.5 at least at one time-point in any substance). Colored rectangles represent transcript abundance 1, 2, 4 and 8 h after injection of the drug
indicated above - ketamine (KET), memantine (MEM) and PCP. Intensity of the color is proportional to the standardized values (between −3 and
3) from each microarray, as displayed on the bar below the heat map image. Hierarchical clustering was performed using Euclidean distance.
Major clusters of drug-responsive genes are arbitrarily described as ‘C1’, ‘C2’ and ‘C3’. The over-representation of the pathways was found statistically
significant with *p < 0.05. Genes involved in the indicated pathways, but displaying different transcription patterns were marked with grey color
Fig. 2 Comparison of the number of genes regulated by ketamine, memantine and PCP in the hippocampus and striatum. Venn diagrams show
the number and overlap of genes altered by drug treatment in the mouse hippocampus and striatum. Lists of transcripts with statistical significance
p < 0.0005 for drug factor after two-way ANOVA in each tissue and absolute fold change greater than 0.3 over saline control (at one of the time points)
were analyzed (Additional file 2)
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case (p < 0.01). In the hippocampus, the analysis indicated
25, 50 and 15 drug-responsive transcripts after treatment
with ketamine, memantine and PCP respectively (at p <
0.0005, absolute fold > 0.3 at least at one time point). We
found 8 genes to be regulated by all of these compounds,
including Plin4, Ppp1r3g and Cdkn1a. In the striatum 38
transcripts were differentially expressed after administra-
tion of ketamine, 55 after memantine and 32 after PCP at
the same statistical threshold (at p < 0.0005, absolute
fold > 0.3). The analysis indicated 7 genes altered by all the
selected drugs in the striatum, for instance Sgk1, Fgf11
and Dnah2 (Additional file 2).
Gene expression profile of ketamine in comparison to
major classes of psychotropic drugs
We performed a comparative analysis of ketamine, meman-
tine and PCP induced gene expression with data from our
previous study, which examined the expression profiles of
18 drugs including antidepressants, antipsychotics and
drugs of abuse [13]. Top 50 genes were identified using
two-way ANOVA for drug and time factors on combined
data followed by correction for multiple testing (corrected
p < 2.3 × 10−21) and then the obtained results were further
used for comparison of the selected psychotropic drugs.
Expression pattern comparison was performed among sets
of the top 50 drug-regulated genes (using data for all the 21
drugs). Hierarchical clustering and principal component
analysis (PCA) were performed to classify ketamine among
other psychotropic drugs based on their gene expression
profiles (Fig. 3). The clustering indicated three major
groups (G1-G3) that contained clinically and pharmaco-
logically divergent drugs, including (G1) anxiolytics, atyp-
ical antipsychotics, imipramine and mianserin; (G2)
psychostimulants, tranylcypromine, bupropion, haloperidol
and buspirone; (G3) NMDA antagonists, fluoxetine, tianep-
tine as well as nicotine, ethanol, heroin and morphine
(Fig. 3a). The gene expression profile of ketamine was most
similar to those of memantine and PCP. The three exam-
ined compounds acting at NMDA receptors were clustered
with two antidepressants and the drugs of abuse.
Three main components of PCA explained 58 % of
variance in gene expression (Fig. 3b). In terms of all
Fig. 3 Comparison of ketamine, memantine and PCP to other psychotropic drugs based on gene expression patterns in the mouse striatum.
Cluster dendrogram (a), PCA plot (b) and heat map (c) were generated based on expression alterations of the top 50 drug-responsive genes
found statistically most significant. The gene expression profiles of ketamine (KET), memantine (MEM) and PCP (PCP) were combined with previously
published profiles of 18 psychotropic drugs from diverse pharmacological and therapeutic classes: mianserin (MIA), imipramine (IMI), fluoxetine (FLU),
bupropion (BUP), tianeptine (TIA), tranylcypromine (TRA), methamphetamine (MET), cocaine (COC), nicotine (NIC), heroin (HER), morphine (MOR), ethanol
(ETO), diazepam (DIA), buspirone (BUS), hydroxizine (HYD), clozapine (CLO), risperidone (RIS) and haloperidol (HAL), with saline (SAL) and naive (NAI) groups
as the controls [13]. The genes were selected based on ANOVA results for drug factor (top 50) at a threshold of nominal p < 10−26 (after
Bonferroni correction p < 10−21). Hierarchical clustering (a) was performed using the measure of Pearson correlation distance and complete
distance linkage methods. The PCA plot (b) displays the pattern of similarity between the selected drugs. The first and second components
are shown on x and y axis respectively, while the values of the third component are coded by color and size of the circles as indicated on
the legend. A comparison of ketamine to antidepressants (c) was based on the patterns of drug-induced transcriptional alterations in the
striatum (at 2 h after the treatment). Drug effects were balanced using modified minimum-maximum normalization, where the maximum
was set up as average from the top 10 fold changes for every drug. Colored rectangles represent expression levels of the top 50 drug-
regulated genes indicated on the right
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three components, the gene expression signature of
ketamine was found to be most similar to PCP, meman-
tine, opioids, ethanol and nicotine. Some similarities in
gene expression profiles were found between ketamine
and risperidone (1st and 2nd components) as well as
ketamine, fluoxetine and tianeptine (3rd component).
Based on the lists of genes correlated with the PCA
components, we assume that the first component repre-
sents drug-induced expression of GR-dependent genes
(explaining 30 % of variance), while the second compo-
nent describes the pattern of expression of activity-
dependent genes (explaining 19 % of variance). The third
component was identified to reflect prolonged drug-
dependent induction of activity-dependent genes (2 and
4 h after treatment).
In addition, we have directly compared molecular pro-
file of ketamine with six antidepressant drugs with dif-
ferent pharmacological profiles (imipramine, mianserin,
fluoxetine, bupropion, tianeptine and tranylcypromine,
Fig. 3c). The analysis was performed using expression
data from the peak (2 h after the drug administration of
transcriptional effects of ketamine) which corresponds
with the onset of antidepressant effects in humans [14].
In general, antidepressant drugs induced diversified pro-
files of gene expression alterations in the striatum. Gene
expression induced by ketamine was most similar to an-
tidepressants blocking monoamine reuptake by inhib-
ition of SERT and DAT, respectively fluoxetine and
bupropion. On the other hand ketamine profile was
most distant from imipramine and mianserin.
Search for ketamine-regulated expression of specific
transcriptional variants
In order to comprehensively examine ketamine-induced
gene expression at the level of separate transcriptional
units we used next-generation sequencing. From the list
of 52 transcripts identified by microarray profiling, 23
genes regulated by ketamine (three-way ANOVA p <
0.05) at 2 h after treatment (absolute fold over saline
control > 0.2) were selected. The mRNA abundance
levels of 79 transcripts assigned to 23 genes were
extracted from the whole-transcriptome dataset. Signifi-
cant differences in gene expression between ketamine-
and saline-treated controls (p < 0.05) were identified for
15 genes. Six of these (Plin4, Nfkbia, Plekhf1, Rgcc,
Csrnp1 and Arrdc2) express a single form of mRNA
contained constitutive exons (CNE). Nine genes showed
ketamine-dependent regulation of alternative transcrip-
tional forms. Classifications of transcription indicated
different types of alternative expression of the regulated
genes. For Sgk1, Tsc22d3 and Hif3a expression of vari-
ants with alternative transcriptional start sites and first
exons (AFE) was detected. The ketamine-induced ex-
pression of specific isoform with alternative last exon
(ALE) and termination site was found for Rhoj. Several
genes express variants with retained intron (IR), includ-
ing Slc2a1, Gjb6 and Map3k6. Moreover, an analysis on
the exon level indicated regulation of Slc2a1 variants
with mutually exclusive exons (MXE). Ketamine-induced
regulation of the expression of selected genes on the
level of genes, transcriptional units and exons is pre-
sented in supplementary results (Additional file 6).
Validation of ketamine-induced alterations in gene
expression
We used quantitative real-time reverse transcription
polymerase chain reaction (qPCR) to validate the results
obtained using high-throughput methods. The experi-
ments were performed using aliquots of the non-pooled
total RNA (n = 6) as well as independent biological repli-
cates (n = 8). The microarray analysis of ketamine effects
in the brain indicated 12 transcripts regulated at the
threshold FDR < 1 %. From this list, three top novel keta-
mine responsive genes Plin4, Sgk1 and Tsc22d3 were se-
lected for validation (Fig. 4). The changes in mRNA
abundance levels were measured in the striatum 2 h
after ketamine or saline administration and in naive ani-
mals. The treatment factor in ANOVA was significant
for all of the transcripts examined by qPCR (Fig. 4b).
The effects of ketamine were similar in two independent
experiments. Greater than 3-fold induction of perilipin 4
(Plin4) mRNA after the treatment was confirmed. Equal
upregulation (about 1.5- to 2-fold) of transcripts for
serum/glucocorticoid regulated kinase 1 (Sgk1) and
TSC22 domain family protein 3 (Tsc22d3) was observed
after acute ketamine administration in the striatum.
Moreover, regulation of the specific variants with alter-
native first exons (AFE) for Sgk1 and Tsc22d3 was vali-
dated using qPCR (Fig. 4a).
Discussion
Clinical trials showed that ketamine can induce an anti-
depressant response within hours from administration
[1]. The antidepressant effects may persist up to two
weeks and has been effective in treatment-resistant pa-
tients [14]. These observations provide hope for poten-
tial use of NMDA receptor antagonists in affective
disorders. Ketamine has also been effective in treatment
of multiple severe neuropsychiatric conditions including
bipolar disorder, post-traumatic stress disorder and
chronic pain [15, 16]. However, the psychotomimetic
and addictive properties of this drug limit its clinical
applications [17]. The neurobiological mechanisms re-
lated to various clinical actions of this prototypic gluta-
matergic “rapid antidepressant” are elusive. A major
difficulty in identifying the underlying mechanism of
ketamine action arises from its complex pharmacological
profile [5]. A dissection of ketamine actions on the
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molecular level may provide insight into particular mecha-
nisms underlying different behavioral effects. Despite the
common use of ketamine in clinical and experimental
studies there are relatively few reports of its action on
gene expression in brain regions involved in the control of
motivation and executive functions [18, 19].
Here, we present the results of ketamine-induced gene
expression profiling and a comparison with psychotropic
drugs from all the major clinical and pharmacological
classes. Additionally, the molecular profile of ketamine
was analyzed on the level of alternative transcriptional
variants using whole-transcriptome resequencing tech-
nology. This study was designed to analyze time course
of gene expression changes in response to ketamine,
PCP and memantine in the striatum and hippocampus.
We found that the three factors (drug, time and tissue)
contributed to different extents to the profile of gene
transcription in the brain. Most differences were ob-
served between the analyzed tissues, however extensive
alterations were also related to the diurnal cycle. These
results are in agreement with previous studies describing
that in the brain, the tissue factor is the main source of
variance in expression profiling experiments [20]. Never-
theless, we found that the effects of the selected NMDA
antagonists are similar in both the analyzed regions, stri-
atum and hippocampus, in terms of top regulated genes.
Both these regions receive dopaminergic inputs from the
ventral midbrain that may explain similar transcriptional
alterations in response to the selected psychoactive com-
pounds [21]. The time course of gene expression alter-
ations was similar for all the NMDA antagonists with
maximum response observed at 2 to 4 h after treatment.
The changes of mRNA abundance induced by the
NMDA antagonists subsided within 8 h following drug
administration. This is consistent with our previous ob-
servation that drug-induced gene expression is transient
[13]. Moreover, we also found that profiles of gene
transcription alterations induced by ketamine, PCP and
memantine are similar. This observation may indicate
that the main effects of the tested drugs on gene expres-
sion are mediated by the blockade of the NMDA
receptor.
Previously published microarray results has been het-
erogeneous in terms of time and tissue selection. A
Fig. 4 Validation of ketamine-induced gene expression alterations. The expression of Plin4, Sgk1 and Tsc22d3 in response to ketamine was measured in
the mouse striatum. a Ketamine-induced expression of specific transcriptional variants was analyzed using next-generation sequencing (n = 4). Variant
classification indicated different biotypes of regulated transcripts (depicted in red) (Additional file 6). b The changes in mRNA abundance levels were
measured 2 h after the administration of ketamine, saline or in naive animals. qPCR analyses were performed using samples from an independent
biological experiment (n = 8). TaqMan probes allow to distinguish between specific transcriptional variants: qPCR probe “1” spans an exon junction of
exons 4 and 5 of Plin4 (ENSMUST00000002908) transcript, qPCR probe “2” spans exons 1 and 2 in Sgk1 (ENSMUST00000120509), qPCR probe “3” spans
exons 1 and 2 in Sgk1 (ENSMUST00000020145), qPCR probe “4” span exons 1 and 2 in Tsc22d3 (ENSMUST00000112995), qPCR probe “5” spans exons 1
and 2 in Tsc22d3 (ENSMUST00000055738). Bars indicate S.E.M, *** p < 0.001, one-way ANOVA drug factor
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comparative meta-analysis is, therefore, difficult to per-
form due to different experimental designs and micro-
array platforms used. For example, gene microarrays
were used to assess the effects of PCP and metham-
phetamine treatment in cerebral cortices. The authors
found that these two compounds regulate a list of function-
ally heterogeneous genes [22]. The identified alterations in
gene expression were linked to psychotomimetic potential
of PCP and methamphetamine. Other studies analyzed the
neurotoxic effects of ketamine and PCP. The effects of
these two NMDA receptor antagonists on gene expression
were analyzed in the developing rat brain in the context of
schizophrenia-like symptoms in animal model [18]. Gene
expression profiling in rat limbic cortex of uncompetitive
NMDA antagonists (memantine and MK-801) indicated
broad actions of these agents on the molecular level [19].
The alterations in mRNA abundance levels were also ana-
lyzed to reveal molecular mechanisms of neuroprotective
effects of memantine. Several gene expression profiling
studies of NMDA antagonists’ effects were performed after
repeated administration. The expression of selected genes
was analyzed after acute and repeated treatment in the cor-
tex, striatum and hippocampus. It was found that chronic
ketamine treatment regulates GABAA receptor alpha 5
subunits in the mouse prefrontal cortex [23].
Interestingly, among the 52 differentially regulated
transcripts were genes encoding proteins associated with
intracellular pathways associated with the development
of mood disorders, MAPK and IL-6 signaling. The first
group includes, for instance, the transcript of the dual-
specificity phosphatase-1 (DUSP1), which is a negative
regulator of MAPK kinase signaling - one of the major
pathways that mediate neuronal plasticity [24]. The sec-
ond group includes the transcript of the serum- and
glucocorticoid-inducible kinase 1 (SGK1), which is im-
plicated in memory formation as well as function of glial
cells [25, 26]. Both these pathways were previously pro-
posed as factors involved in the mechanisms of depres-
sive disorders associated with chronic stress [27–29].
Other group of transcripts regulated in response to
NMDA antagonists contains genes involved in insulin-
mediated cellular signaling pathway, including glucose
transporter Slc2a1. The regulation of this pathway is po-
tentially interesting in the context of connection be-
tween depression and insulin resistance in diabetic
patients [30].
The observed effects on gene expression may correspond
to alterations detected on the protein level. Previous results
suggested involvement of molecular mechanisms concern-
ing mTOR, BDNF and eEF2 kinase pathways in ketamine
action [11, 31]. These processes are related to the develop-
ment of depression through synaptic remodeling and
immunomodulation [32]. Ketamine has been shown to in-
duce expression of synapse-associated proteins through the
rapid activation of mTOR-regulated ERK and Akt signaling
pathways [11]. Moreover, mTOR signaling is involved in
the resetting of the circadian clock by regulating the ex-
pression of circadian proteins [33]. The elevated transcrip-
tion of the period 1 (Per1) gene in response to ketamine
may be a consequence of increased activity of mTOR-
pathway. Both the molecular levels of regulation, tran-
scripts and proteins expression, form a control system for
drug-induced plastic alterations in the brain. In summary,
our results show that ketamine affects expression of several
genes potentially involved in neuronal plasticity. It should
be noted though, that these changes are not exclusive to
ketamine and are also observed in case of other NMDA
antagonists we tested.
There were several cases where treatment with NMDA
antagonists affected the expression of GR-dependent tran-
scripts that are also associated with development of
neuropsychiatric disorders. The Fkbp5 gene is a prime ex-
ample, as the gene was connected with sensitivity to rapid
effects of treatment with antidepressants [34]. Expression
of specific Fkbp5 variants is GR-dependent while at the
same time the FKBP5 protein is a critical regulator of GR
activity [35]. Further examples include the hypoxia indu-
cible factor 3 alpha subunit (Hif3a), whose expression was
found to be increased in schizophrenic and bipolar pa-
tients [36] or Sgk1 and Tsc22d3, which were associated
with high interleukin (IL)-6 levels in patients suffering
from the major depressive disorder [37]. In all three cases
ketamine treatment induced only expression of the short
transcriptional variants, which again points at the import-
ance of analysis of gene expression at transcript rather
than gene level [38]. The results indicate that ketamine
may activate the hypothalamic-pituitary-adrenal axis and
release of glucocorticoids from adrenal glands [25]. Thor-
ough analysis of this systemic response may provide
further insight into the interaction between the effects of
psychotropic drugs, stress and glucocorticoids. The ob-
served gene expression alterations reveals several aspects
of the complex molecular profile of drug-induced alter-
ations in the brain.
Despite the similarity between the NMDA antagonists,
we identified transcripts with diverse regulation induced
by these drugs in the selected brain regions. Differences
between ketamine, memantine and PCP may provide
important information for the understanding of rapid
antidepressant effects. PCP decreases immobility time, a
depression-like behavior in the forced swim test in mice,
but elicits more intense psychotomimetic effects than
ketamine. On the other hand, memantine did not show
fast antidepressant-like properties in animal models [10].
Our findings have raised concerns regarding the possi-
bility to dissect unique pattern of ketamine effects by
using the comparison to other psychotropic drugs. We
and others used gene expression profiling to predict
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properties of the psychoactive compounds [13, 39].
Here, we used the large microarray data-set to compare
ketamine effects with 20 psychotropic drugs from vari-
ous clinical and pharmacological groups.
The profiles of gene expression alterations induced by
the tested NMDA antagonists were most similar to some
antidepressants and drugs of abuse. Specifically, the pro-
files were similar to the monoaminergic antidepressants,
fluoxetine and tianeptine. The anti-anhedonic and anti-
depressant effects of ketamine are rapid in comparison
to typical antidepressants. However, the similarities in
the patterns of drug-induced gene expression may indi-
cate shared neurobiological effects. A recent clinical re-
port indicated that response to antidepressant treatment
is accelerated by the co-administration with methylphen-
idate [40]. It is possible that the combination of various
ketamine effects, including boosting serotonin and dopa-
mine activities, may lead to earlier manifestation of anti-
depressant action [5, 41]. As it was anticipated, the
NMDA antagonists reveal relatively distinct molecular
profiles from neuroleptics and atypical antidepressant
mianserine. Interestingly, the gene expression profile of
ketamine was more similar of opioids, ethanol and nico-
tine than to psychostimulants. It was previously de-
scribed that ketamine has mild agonistic activity on
opioid receptors and modifies the responsiveness [42].
These effects of ketamine on opioid system may result
in expression of genes also regulated in the striatum by
opioids and ethanol [43]. Thus, this observation sup-
ports the claim that ketamine may have addictive poten-
tial which substantially limits its clinical application.
Conclusions
Gene profiling in limbic brain areas indicated several
novel aspects of molecular action of ketamine as well as
two other tested NMDA antagonists, memantine and
PCP. The presented molecular classification of these
drugs positioned them between antidepressants and
drugs of abuse. We believe that the obtained profile of
ketamine-induced gene expression reflects combination
of its pharmacological and neurobiological properties.
The unique clinical profile of ketamine that includes
psychotomimetic, anti-anhedonic and addictive effects is
associated with specific transcriptional alterations. This
combination of pharmacological and molecular effects
might be difficult to achieve by other compounds even
with similar chemical characteristics.
Methods
Animals
Adult male (8 to 10 weeks old) C57BL/6 J mice (Jackson
Laboratory, Bar Harbor, ME, USA) were housed 6 to 10
per cage under a 12 h dark/light cycle with free access
to food and water. Animals weighing 20 to 30 g were
used throughout the experiments. The animal protocols
were approved by the local Bioethics Commission at the
Institute of Pharmacology PAS.
Drug treatment
Mice were injected i.p. (vol. 10 ml/kg) with ketamine
(20 mg/kg), PCP (5 mg/kg) or memantine (15 mg/kg).
The animals were killed by decapitation 1, 2, 4 or 8 h
after a single injection along with the saline-treated and
naive control groups (6 animals per group). The effective
doses of the NMDA receptor antagonists were based on
the literature, particular attention being paid to their
pharmacological effects in C57BL/6 J mice [44–46]. The
doses were selected to provide reasonable comparison of
drugs’ effects on the molecular level.
Tissue collection and RNA isolation
Samples containing the hippocampus and striatum were
collected. The dissection procedure was performed as
previously described [13]. Tissue samples were placed in
RNAlater reagent (Qiagen Inc., Valencia, CA, USA) and
preserved at −70 °C. Samples were homogenized in 1 ml
Trizol reagent (Invitrogen, Carlsbad, CA, USA). RNA
was isolated following the manufacturer’s protocol and
further purified using the RNeasy Mini Kit (Qiagen Inc.).
The total RNA concentration was measured using a
ND-1000 Spectrometer (NanoDrop Technologies Inc.,
Montchanin, DE, USA). The RNA quality was assessed
using Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA,
USA).
Microarray hybridization
A starting amount of 200 ng high-quality total RNA
(pooled 1:1 from two animals) was used to generate
cDNA and cRNA with the Illumina TotalPrep RNA
Amplification Kit (Illumina Inc., San Diego, CA, USA).
The resulting cDNA served as a template for in vitro
transcription with T7 RNA polymerase and biotin-
labeled UTP to generate multiple copies of biotinylated
cRNA. Each cRNA sample (1.5 μg) was hybridized over-
night to MouseWG-6 BeadChip array (Illumina); subse-
quently, chips were washed, dried and scanned with the
BeadArray Reader (Illumina). Raw microarray data were
generated using BeadStudio v3.0 (Illumina). A total of
120 Illumina MouseWG-6 v2 microarrays were used
(three independent arrays per group). Samples from 2
mice were pooled per microarray, 3 biological replicates
were used per time point and 12 arrays per each drug.
Distribution of samples was balanced across array plates
and hybridization batches.
Microarray data analysis
Analysis and quality control of 120 microarrays was per-
formed using BeadArray R package v2.14.1. After
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background subtraction, the data were normalized using
quantile normalization and then log2-transformed. The
obtained signal was taken as the measure of mRNA
abundance derived from the level of gene expression.
Statistical analysis of the results was performed using
three-way ANOVA (for the drug, time and tissue fac-
tors) followed by correction for multiple testing using
false discovery rate (percent FDR). The FDR was esti-
mated using the Benjamini and Hochberg method.
Furthermore, obtained data were subjected to two-way
ANOVA for drug and time as factors for each drug and
tissue separately. All statistical analyses were performed in
R software version 3.1.1. Gene annotation tool Enrichr
was used to identify over-represented ontological groups
among the gene expression patterns and to group genes
into functional classifications [47]. The visualization of
microarray results was performed using dChip software.
Principal component analysis (PCA) and hierarchical
clustering
We used unsupervised hierarchical clustering and princi-
pal component analysis (PCA) of the top drug-responsive
transcripts to classify the psychotropic drugs. Hierarchical
clustering was performed using the measure of Pearson
correlation distance and complete distance linkage
methods. The gene expression profiles of ketamine (KET),
memantine (MEM) and PCP in striatum were combined
with previously published profiles of 18 psychotropic
drugs from diverse pharmacological and therapeutic clas-
ses with saline and naive groups as controls [13]. To re-
duce batch effects between the experiments, the analyses
were performed on log2 fold changes over corresponding
saline controls. PCA was performed based on expression
alterations of the top 50 drug-responsive genes found sta-
tistically most significant in two-way ANOVA with drug
and time as factors (nominal p < 1 × 10−25, after Bonferroni
correction p < 2.3 × 10−21). R package FactoMineR version
1.29 was used for the analysis and the PCA was done based
on correlation matrix.
Quantitative PCR
Reverse transcription was performed using Omniscript
Reverse Transcriptase (Qiagen Inc.). qPCR reactions
were performed using TaqMan® Gene Expression Assays
(Sgk1 - Mm00441387_g1; Tsc22d3 - Mm00726417_s1;
Plin4 Mm00491061_m1) and isoform-specific TaqMan®
probes designed using the Custom TaqMan® Assay De-
sign Tool (Life Technologies, Foster City, CA, USA).
The reactions were run on the CFX96 Real-Time system
(BioRad). Each template was generated from an individ-
ual animal. Samples from two independent experiments
were analyzed (n = 6 and 8 respectively). Expression of
the hypoxanthine-guanine phosphoribosyltransferase 1
(Hprt1) transcript was quantified to control for variation
in cDNA amounts. The abundance of RNA was calculated
as 2‐ (threshold cycle). Data were analyzed using one-way
ANOVA followed by Tukey’s HSD multiple comparison
test.
Whole-transcriptome resequencing
High-quality total RNA (1 μg) was ribo-depleted using
the RiboMinusTM Eukaryote Kit v2 (Ambion). rRNA-
depleted RNA was used as the template for preparation
of RNA-seq library generated using the Ion Total RNA-
seq Kit v2 system according to the manufacturer’s proto-
col. For template preparation, we performed emulsion
PCR (ePCR) using the Ion OneTouchTM 2 Instrument
and the Ion PITM Template OT2 200 Kit v3. Sequen-
cing was performed using an Ion PITM Sequencing 200
Kit v3 and the Ion PITM Chip v2 (Life Technologies).
The template-positive ion sphere particles (ISPs) were
loaded onto an Ion PITM Chip v2 and sequenced (single
end reads >100 bp).
NGS data analysis
NGS data quality was verified using FastQC. The RNA-
seq read alignment was performed using TopHat 2.0.1
and Bowtie 2.1.0. IntersectBed v2.14.2 was used to deter-
mine the counts on gene and exon levels. Statistical sig-
nificance was analyzed using edgeR package v3.10.2.
Additionally, the transcript FPKM (Fragments Per Kilo-
base of transcript per Million fragments mapped) levels
were quantified using the Cufflinks package. The ana-
lyses were performed using R software v3.0.1. Transcript
annotation (biotype and event attributes) and classifica-
tion was performed using the BioMart interface to the
Ensembl gene database [38].
Ethics approval
The animal protocols were approved by the local Bioethics
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Additional file 1: Results from three-way ANOVA for 52 drug-responsive
transcripts (FDR for drug factor < 0.01 and absolute fold > 0.5 at least at one
time point for any substance) are included. For each transcript a p-value and
percent FDR for drug, time and tissue factors and all the interactions are
presented. (XLSX 19 kb)
Additional file 2: The lists of transcript IDs and gene names
corresponding to Venn diagrams for the hippocampus and striatum are
presented in the first and second sheet respectively. Column names
indicate which drugs alter the expression of listed transcripts. In case
where only one substance name is listed, the altered expression level is
drug-specific (at p < 0.0005 from two-way ANOVA for drug and time as
factors and absolute fold > 0.3 at least at one of the time points in the
analyzed tissue). (XLSX 12 kb)
Additional file 3: The results of functional enrichment analysis
performed with Enrichr tool for two clusters of genes significantly altered
by the selected NMDA antagonists. The table consists of an enriched term, a
number of input genes in the pathway (overlap), p-value (p < 0.05), z-score,
combined score (computed as logarithm from p-value from the Fisher’s exact
test multiplied by the z-score of the deviation from the expected rank) and
the overrepresented genes. (XLSX 12 kb)
Additional file 4: The lists of probe IDs and gene names obtained in the
comparison between tissues based on two-way ANOVA results (at p < 0.0005
for the drug factor, absolute fold > 0.3 at least at one of the time points).
Transcripts regulated by drug treatment in the hippocampus or striatum
specifically and a list of genes altered in both tissues are presented.
(XLSX 10 kb)
Additional file 5: The pattern of gene expression alterations induced by
the selected NMDA receptor antagonists over the time-course (1–8 h
after treatment) in the hippocampus and striatum. (PDF 155 kb)
Additional file 6: The table summarizing results of gene expression
profiling of ketamine effects in the mouse striatum using RNA-seq (n = 4).
In the first sheet 23 genes regulated by ketamine selected from the
microarray profiling are listed with their chromosome location, fold
change over control, p-value and FDR. The second sheet presents a list of
the 15 selected genes with significant differences in expression between
ketamine-treated and saline controls (p < 0.05) with annotated transcripts
abundance and fold change of drug-induced alterations for each regulated
transcript. Transcripts were annotated using the Ensembl gene database.
For each transcript the analysis on exon level (third sheet) was performed
showing exon location on chromosome, fold change, p-value, FDR and the
number of reads for each exon and sample. The last sheet contains a list of
transcript biotypes annotation and classification using the BioMart interface
to the Ensembl gene database. (XLSX 81 kb)
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